Evidence map›Paper›PMID 35721113›Full record

ArticleFrontiers in pharmacology2022

The XPO1 Inhibitor KPT-8602 Ameliorates Parkinson's Disease by Inhibiting the NF-κB/NLRP3 Pathway.

Shuhan Liu, Shengxiang Wang, Runze Gu, Na Che, Jing Wang, Jinbo Cheng, Zengqiang Yuan, Yong Cheng, Yajin Liao

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
1.0field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 13 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Review
  9. Review
  10. Nuclear transport proteins: structure, function, and disease relevance.Signal transduction and targeted therapy · 2023
    Review
  11. Review
  12. Review
  13. Review
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Shuhan LiuCenter on Translational Neuroscience, College of Life and Environmental Sciences, Minzu University of China, Beijing, China.
Shengxiang WangCenter on Translational Neuroscience, College of Life and Environmental Sciences, Minzu University of China, Beijing, China.
Runze GuCenter on Translational Neuroscience, College of Life and Environmental Sciences, Minzu University of China, Beijing, China.
Na CheCenter on Translational Neuroscience, College of Life and Environmental Sciences, Minzu University of China, Beijing, China.
Jing WangCenter on Translational Neuroscience, College of Life and Environmental Sciences, Minzu University of China, Beijing, China.
Jinbo ChengCenter on Translational Neuroscience, College of Life and Environmental Sciences, Minzu University of China, Beijing, China.
Zengqiang YuanCenter on Translational Neuroscience, College of Life and Environmental Sciences, Minzu University of China, Beijing, China.
Yong ChengCenter on Translational Neuroscience, College of Life and Environmental Sciences, Minzu University of China, Beijing, China.
Yajin LiaoCenter on Translational Neuroscience, College of Life and Environmental Sciences, Minzu University of China, Beijing, China.
Minzu University of China · CNInstitute of Basic Medical Sciences of the Chinese Academy of Medical SciencesState Ethnic Affairs Commission · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Exportin 1 (XPO1) is an important transport receptor that mediates the nuclear export of various proteins and RNA. KPT-8602 is a second-generation inhibitor of XPO1, demonstrating the lowest level of side effects, and is currently in clinical trials for the treatment of cancers. Previous studies suggest that several first-generation inhibitors of XPO1 demonstrate anti-inflammation activities, indicating the application of this drug in inflammation-related diseases. In this study, our results suggested the potent anti-inflammatory effect of KPT-8602

Indexed as

KPT-8602NF-κBNLRP3 inflammasomeParkinson’s diseaseXPO1

Identifiers

PMID35721113
PMCPMC9200340
OpenAlexW4281967800

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.